目的 探究蘇黃止咳膠囊輔助治療咳嗽變異性哮喘的療效及安全性。方法 選擇2013年2月—2014年12月期間洪澤縣人民醫(yī)院收治的100例咳嗽變異性哮喘患者, 按照隨機(jī)數(shù)字法分為治療組和對(duì)照組, 每組各50例。對(duì)照組患者給予常規(guī)止咳及對(duì)癥治療, 治療組患者則在對(duì)照組基礎(chǔ)上服用蘇黃止咳膠囊輔助治療。觀察兩組臨床癥狀的消失時(shí)間及不良反應(yīng)發(fā)生情況。治療前后采用肺功能儀測(cè)定用力肺活量(FVC)、第一秒用力呼氣容積(FEV1)、呼氣峰值流量(PEF)等肺功能指標(biāo)。采用酶聯(lián)免疫吸附法測(cè)定血清IL-6、TNF-α水平。采用流式細(xì)胞儀檢測(cè)CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺等細(xì)胞免疫指標(biāo)。結(jié)果 治療后, 治療組總有效率為94.0%、不良反應(yīng)發(fā)生率為8.0%, 對(duì)照組分別為70.0%和50.0%, 差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組咳嗽癥狀起效時(shí)間、氣喘及哮鳴音消失時(shí)間、咳嗽消失時(shí)間明顯短于對(duì)照組(P<0.05)。治療前兩組肺功能, 血清IL-6、TNF-α水平, CD3⁺、CD4⁺、CD4⁺/CD8⁺、CD8⁺等差異均無(wú)統(tǒng)計(jì)學(xué)意義, 治療后各指標(biāo)兩組組內(nèi)及組間差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 蘇黃止咳膠囊輔助治療咳嗽變異性哮喘患者, 能夠明顯提高臨床療效, 改善肺功能, 且具有較好的安全性, 其機(jī)制可能與提高CD3⁺、CD4⁺, 下調(diào)CD8⁺, 減少IL-6、TNF-α促炎癥細(xì)胞因子分泌, 增強(qiáng)機(jī)體細(xì)胞免疫功能有關(guān)。

Objective To explore the effect and safety of Suhuang Zhike Capsule used in the treatment of cough variant asthma. Methods From February 2013 to December 2014, 100 cases with cough variant asthma in our hospital were selected and divided into treatment group and control group, 50 cases in each group. The patients in the control group were given conventional cough treatment, while the patients in the treatment group were given Suhuang Zhike Capsule. the disappear time of clinical symptoms and adverse reaction between the two groups were observed: The lung function indices such as FVC, FEV1 and PEF were detected by Spiromete; The levels of serum IL-6 and TNF-α were measured by ELISA, and the cellular immunity indexes of CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ etc were determined by FACS. Results After the treatment, the total effective rate of the the patients in the treatment group was 94.0%, the incidence of adverse reactions was 8.0%, while the control was 70.0% and 50.0%, respectively, the differences were statistically significant (P < 0.05); The onset time of effect on cough, the disappear time of asthma and wheezing sound, and cough lose time of the patients in the treatment group were significantly shorter than those of the patients in the control group (P < 0.05). Before the treatment, the lung function, serum levels of IL-6 and TNF-a, and CD3+, CD4+, CD8+, C CD4+/D8+, etc in the two groups were no statistically significant difference (P > 0.05). But after the treatment, the differences were no statistically significance in each group. Conclusion Suhuang Zhike Capsule used in the treatment of cough variant asthma can obviously improve the clinical curative effect and lung function and have good security. The mechanism may be related to the increase of CD3+, CD4+, CD8+, decrease of IL-6 and TNF-α secretion, and enhancement of the cellular immune function.